Leptomeningeal metastasis in breast cancer – a systematic review
PDF | HTML | How to cite
Metrics: PDF 2559 views | HTML 3337 views | ?
Brian J. Scott1, Nancy A. Oberheim-Bush2 and Santosh Kesari3
1 Department of Neurology, Lahey Hospital and Medical Center, Burlington, Massachusetts, USA
2 Department of Neurology, University of California, San Francisco, California, USA
3 Translational Neuro-Oncology Laboratories and Department of Neurosciences, Moores UCSD Cancer Center, La Jolla, California, USA
Brian J. Scott, email:
Keywords: leptomeningeal metastasis, carcinomatous meningitis, breast cancer, central nervous system metastasis, intrathecal chemotherapy
Received: June 15, 2015 Accepted: September 12, 2015 Published: November 02, 2015
Background: There is limited data on the impact of specific patient characteristics, tumor subtypes or treatment interventions on survival in breast cancer LM.
Methods: A systematic review was conducted to assess the impact of hormone receptor and HER-2 status on survival in breast cancer LM. A search for clinical studies published between 1/1/2007 and 7/1/2012 and all randomized-controlled trials was performed. Survival data from all studies are reported by study design (prospective trials, retrospective cohort studies, case studies).
Results: A total of 36 studies with 851 LM breast cancer subjects were identified. The majority (87%) were treated with intrathecal chemotherapy. Pooled median overall survival ranged from 14.9-18.1 weeks depending on study type. Breast cancer LM survival (15 weeks) was longer than other solid tumor LM 8.3 weeks and lung cancer LM 8.7 weeks, but shorter than LM lymphoma (15.4 versus 24.2 weeks). The impact of hormone receptor and HER-2 status on survival could not be determined.
Conclusions: A median overall survival of 15 weeks in prospective studies of breast cancer LM provides a historical comparison for future LM breast cancer trials. Other outcomes including the impact of molecular status on survival could not be determined based on available studies.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.